


## AMENDMENTS TO THE CLAIMS

**Claims 1 to 27** (cancelled)

**Claim 28** (previously presented)

A compound of the formula



III

wherein  $R_3$  is selected from the group consisting of hydrogen, methyl and  $-OH$ ,

$R_4$  is hydrogen or  $-OH$ ,

T is selected from the group consisting of hydrogen, methyl,  $-CH_2-CONH_2-$ ,  $-CH_2-CN$ ,

$-(CH_2)_2-NH_2$  and  $-(CH_2)_2-Nalk_2^+X^-$ , alk is alkyl of 1 to 8 carbon atoms,  $X'$  is halogen,

Y is selected from the group consisting of hydrogen, -OH, halogen and -SO<sub>2</sub>H and salts thereof, W is hydrogen, or -OH,  
Z is hydrogen or methyl or a non-toxic pharmaceutically acceptable acid addition salt thereof.

**Claim 29** (previously presented)

A compound of claim 28 selected from the group consisting of


1-([4-oxo-N2-(12-methyl-1-oxotetradecyl)-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B,

1-[N2-[[4'-octyloxy]-[1,1'-biphenyl]-4-yl]-carbonyl]-4-oxo-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B,

1-[N2-[[4-[4-[4-(pentyloxy)phenyl]-1-piperazinyl]-phenyl]-carbonyl]-4-oxo-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandin B.


**Claim 30** (previously presented)

A compound of the formula



**Claim 31 (currently amended)**

A compound of the formula



wherein R is selected from the group consisting of alkyl and cycloalkyl of up to 30 carbon atoms optionally containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, at least one heterocycle and acyl of up to 30 carbon atoms optionally containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen and/or at least one heterocycle,

R<sub>3</sub> is selected from the group consisting of hydrogen, methyl and -OH,

R<sub>4</sub> is hydrogen or -OH,

T is selected from the group consisting of hydrogen, methyl, -CH<sub>2</sub>-CONH<sub>2</sub>-, -CH<sub>2</sub>-CN, -(CH<sub>2</sub>)<sub>2</sub>-NH<sub>2</sub> and -(CH<sub>2</sub>)<sub>2</sub>-Nalk<sub>2</sub><sup>+</sup>X<sup>-</sup>, alk is alkyl of 1 to 8 carbon atoms, X<sup>-</sup> is halogen,

Y is selected from the group consisting of hydrogen, -OH, halogen and -SO<sub>3</sub>H and salts thereof, W is hydrogen, or -OH,


Z is hydrogen or methyl or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

~~R<sub>3</sub> is selected from the group consisting of hydrogen, methyl and -OH,~~

~~R<sub>4</sub> is hydrogen or -OH~~

**Claim 32 (previously presented)**

A compound of the formula




III

R<sub>3</sub> is selected from the group consisting of hydrogen, methyl and -OH,

R<sub>4</sub> is hydrogen or -OH.

A compound of the formula



IV

R<sub>4</sub> is hydrogen or -OH,

T is selected from the group consisting of hydrogen, methyl,  $-\text{CH}_2\text{-CONH}_2$ -,  $-\text{CH}_2\text{-CN}$ ,  $-(\text{CH}_2)_2\text{-NH}_2$  and  $-(\text{CH}_2)_2\text{-Nalk}_2^+\text{X}^-$ , alk is alkyl of 1 to 8 carbon atoms, X' is halogen,

Y is selected from the group consisting of hydrogen, -OH, halogen and -SO<sub>3</sub>H and salts thereof, W is hydrogen, or -OH,

Z is hydrogen or methyl or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

**Claim 34 (new)**

A method of treating an ailment in people caused by exposure to a fungus comprising administering to people in need thereof an antifungally effective amount of an echinocandin B derivative or its acid addition salt.

**Claim 35 (new)**

The method of claim 34 in which said fungus is selected from the group consisting of *Candida albicans*, *Candida glabrata*, *krusei*, *tropicalis*, *pseudotropicalis*, *parapsilosis*, *Aspergillus fumigatus*, *Aspergillus flavus*, and *Cryptococcus neoformans*.

**Claim 36 (new)**

The method of claim 34 in which said ailment is selected from the group consisting of digestive, urinary, vaginal or cutaneous candidoses, cryptococcoses, neuromeningeal, pulmonary or cutaneous cryptococcoses, bronchopulmonary and pulmonary aspergilloses and invasive aspergilloses of immunocompromise.

**Claim 37 (new)**

The method of claim 34 which is directed to the prevention of mycosic ailments in people with congenital or acquired immune compromise.

**Claim 38 (new)**

The method of claim 34 in which said derivative of echinocandin B or its acid addition salt is administered in the form of an injectable preparation.

**Claim 39 (new)**

The method of claim 34 in which said derivative of echinocandin B or its acid addition salt is administered in the form of a solution.

**Claim 40 (new)**

The method of claim 34 in which the effective amount ranges from about 50 mg to about 300 mg per day.

**Claim 41 (new)**


The method of claim 39 in which said solution is obtained by dissolving a powder of said derivative of echinocandin B or its acid addition salt in an appropriate medium.

**Claim 42 (new)**

The method of claim 41 in which said appropriate medium comprises apyrogenic sterile water.

**Claim 43 (new)**


A compound of the formula:



wherein

R<sub>1</sub> is hydrogen,

R<sub>2</sub> is an alkyl of two carbons interrupted with






a and b are each hydrogen,

R<sup>3</sup> is methyl,

R<sup>4</sup> is -OH,

R is



T, Y and W are each hydrogen, and

Z is methyl or

a pharmaceutically acceptable acid addition salt thereof.